US2009017073A1PendingUtilityA1
Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
Est. expiryMar 27, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61P 37/02A61P 31/04C07K 14/4702A61K 38/04G01N 33/5041G01N 2510/00C07K 9/005A61K 38/05G01N 33/5011G01N 33/56911C07K 5/0215G01N 33/5008G01N 33/502G01N 33/5017A61P 29/00Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.
Claims
exact text as granted — not AI-modified1 - 15 . (canceled)
16 . A method for providing an immune response in a host, which comprises administering an amount effective to promote an immune response of a composition comprising an antigen and a tripeptide having the structure L-Ala-D-Glu-mesoDAP, or a biological derivative or a peptidomimetic thereof, wherein the amino acid Ala of said tripeptide is not linked to a N-acylmuramic acid.
17 - 18 . (canceled)
19 . The method of claim 16 , wherein the host is human or a warm-blooded animal.
20 - 34 . (canceled)
35 . The method of claim 16 , wherein the L-Ala is replaced with D-Ala.
36 . The method of claim 16 , wherein the antigen is from a Gram negative bacterium.
37 . The method of claim 36 , wherein the Gram negative bacterium is chosen from Escherichia coli, Shigella flexneri, Neisseria meningitidis , and Salmonella typhimurium.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.